Clinical trials: LAM, active
Tuberous Sclerosis, Lymphangioleiomyomatosis
TSC Biosample Repository and Natural History Database
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database.
- Trial name
- NCT05676099
- Testing
- Phlebotomy, Buccal (cheek) swab, Genetic Testing
- Where
- 26 sites in United States, Canada
- Volunteers
- 5,000 people
- Sponsor
- National Tuberous Sclerosis Association
HIV Infection, Antiretroviral Therapy
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up
A single-center, open-label, randomized pilot clinical trial between March 2025 and March 2026 at the Hospital de Infectología "La Raza" National Medical Center in Mexico City.
- Conditions
- HIV Infection, Antiretroviral Therapy, Lentivirus Infections
- Trial name
- TLALOC-2 (NCT07678268)
- Testing
- Dual therapy: darunavir/cobicistat + lamivudine, Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine
- Where
- Mexico
- Volunteers
- 78 people
- Sponsor
- Instituto Mexicano del Seguro Social
Rett Syndrome
Lamivudine as a Novel Clinical Effort for Rett Syndrome
Rett syndrome (RTT) is a rare genetic neurodevelopmental disorder caused primarily by mutations in the MECP2 gene, leading to progressive impairments in motor function, communication, and behavior following an initial period of…
- Trial name
- LANCE (NCT07640503)
- Testing
- Lamivudine
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Maria Denise Fernandes Carvalho de Andrade
Chronic Respiratory Diseases, Cystic Fibrosis
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory…
- Conditions
- Chronic Respiratory Diseases, Cystic Fibrosis, Lymphangioleiomyomatosis, Hypersensitivity Pneumonitis
- Trial name
- NCT05727852
- Testing
- Breath test using the Compact PTR-TOF-MS, Portable cardiac monitor "CardioQvark", Assessment of arterial stiffness using the VaSera VS-1500N
- Where
- Russia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
HIV Infections
Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up
This is a phase 4, randomized, controlled, open-label, single-center clinical trial conducted at the Hospital de Infectología, National Medical Center "La Raza." The study employs a non-inferiority design with follow-up…
- Trial name
- TLACAELEL (NCT07138144)
- Testing
- Standard Medical Therapy, dual therapy
- Where
- Mexico
- Volunteers
- 156 people
- Sponsor
- José Antonio Mata Marín
Tuberculosis
Evaluating Next Generation LAM Assays and Molecular Diagnostics (POC and Near POC) for the Diagnosis of TB Among People With Presumptive TB: a Prospective Multicentre Diagnostic Accuracy Study
This prospective multicentre study is planned to evaluate the next generation LAM assays and molecular diagnostics (POC and near POC) among people with presumptive Tuberculosis.
- Trial name
- DriveDx4TB (NCT06019052)
- Volunteers
- 1,890 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
HIV - Human Immunodeficiency Virus, Obesity
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
Background:Historically, HIV infection was associated with significant weight loss. However, weight gain is now commonly observed after initiating antiretroviral therapy (ART), particularly in individuals underweight at baseline.
- Conditions
- HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity
- Trial name
- COATL (NCT07075146)
- Testing
- DOR/3TC/TDF, BIC/FTC/TAF
- Where
- Mexico
- Volunteers
- 306 people
- Sponsor
- José Antonio Mata Marín
Tuberous Sclerosis Complex, Lymphangioleiomyomatosis
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
- Trial name
- NCT06160310
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- David M. Ritter
HIV-1-infection, Opioid Use Disorder
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
The goal of this clinical trial is to determine the efficacy of Dolutegravir/Lamivudine (DTG/3TC), or "Dovato", in virally-suppressed (HIV-1 RNA < 200 copies/mL) individuals receiving opioid agonist therapy such as methadone…
- Trial name
- NCT06580873
- Testing
- DOVATO
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
HIV-1-infection
Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully
The main objective of the MODULO trial is to compare (non-inferiority) the capacity of DOR/3TC and DTG/3TC two-drug regimens of maintain virological success at W48 in people living with HIV virus ( PLWH) with suppressed HIV…
- Trial name
- MODULO (NCT06774872)
- Testing
- Doravirine 100Mg Tab and Lamivudine 300 Mg Tab, Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab
- Where
- France
- Volunteers
- 408 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Mild Cognitive Impairment
A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)
To assess the ability of lamivudine to lower the levels of neurocognitive impairment biomarkers in the plasma of patients with MCI and positive AD biomarkers in a 24 weeks-treatment period.
- Trial name
- NCT06519357
- Testing
- Lamivudine 300 MG
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Extensive Stage Lung Small Cell Carcinoma
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
This phase II trial studies the effect of lamivudine in combination with standard of care chemoimmunotherapy in treating patients with extensive stage small cell lung cancer.
- Trial name
- NCT04696575
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Roswell Park Cancer Institute
HIV/AIDS
Simplified Treatment of Anti-retrovirus in China (C-STAR)
To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.
- Trial name
- NCT03603977
- Testing
- Lpv/r+3TC
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV Infection, Metabolic Syndrome
Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience
Background: The primary goal of antiretroviral therapy is to prevent HIV-associated morbidity and mortality. The effectiveness of first-line regimens is supported by a large number of clinical trials; current concerns focus on…
- Conditions
- HIV Infection, Metabolic Syndrome, Antiretroviral Treatment
- Trial name
- TEOTL (NCT07031063)
- Testing
- DTG/3TC, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
- Where
- Mexico
- Volunteers
- 124 people
- Sponsor
- Instituto Mexicano del Seguro Social
HIV
Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients
Non-interventional, retrospective, single arm study of individuals who have initiated a DTG/3TC regimen. Medical chart will be reviewed by the investigators.
- Trial name
- NCT06928090
- Testing
- DTG + 3TC FDC
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Chungnam National University Hospital
Lymphangioleiomyomatosis
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Background: Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow of air.
- Trial name
- NCT01799538
- Testing
- albuterol inhaler, albuterol nebulizer, PFT
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
LAM, Lymphangioleiomyomatosis
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
- Trial name
- MILED (NCT03150914)
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Cincinnati
Tuberculosis, HIV
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice…
- Trial name
- DOVETAIL (NCT06497465)
- Testing
- Dolutegravir 50mg Tab, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
- Where
- 5 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- Johns Hopkins University
HIV-1-infection
Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women
Protocol Number: FH-94 Study Objetives: Primary: To evaluate the virological response to Dolutegravir/Lamivudine in naive pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed…
- Trial name
- PREDUAL (NCT07616739)
- Testing
- Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)
- Where
- 10 sites in Argentina, Brazil
- Volunteers
- 210 people
- Sponsor
- Fundación Huésped
Relapsed/Refractory Solid Tumors
Lamivudine for Solid Tumors
Single arm, set dose clinical trial of Lamivudine for Relapsed Refractory Solid Tumors. Accrual 6-24 patients, within 2 years, study completion within 3 years at Mount Sinai Health System.
- Trial name
- NCT06494579
- Testing
- Lamivudine, PD-L1 Blocker
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Thomas Marron